2023
Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis
Luukkonen P, Sakuma I, Gaspar R, Mooring M, Nasiri A, Kahn M, Zhang X, Zhang D, Sammalkorpi H, Penttilä A, Orho-Melander M, Arola J, Juuti A, Zhang X, Yimlamai D, Yki-Järvinen H, Petersen K, Shulman G. Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2217543120. PMID: 36669104, PMCID: PMC9942818, DOI: 10.1073/pnas.2217543120.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseLiver fibrosisLiver diseaseCommon chronic liver diseaseChronic liver diseaseFatty liver diseaseRisk of fibrosisDistinct mouse modelsPyrimidine catabolismNonalcoholic steatohepatitisMouse modelTherapeutic targetFibrosisDihydropyrimidine dehydrogenaseHuman liverA variantCommon variantsMetabolomics approachDiseaseMiceInhibitionCatabolismKnockdownSteatohepatitisGimeracil
2017
Non-alcoholic fatty liver disease: An expanded review
Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World Journal Of Hepatology 2017, 9: 715-732. PMID: 28652891, PMCID: PMC5468341, DOI: 10.4254/wjh.v9.i16.715.Peer-Reviewed Original ResearchNon-alcoholic fatty liver diseaseNAFLD patientsInsulin resistanceRisk factorsDevelopment of NAFLDTreatment of NAFLDFatty liver diseaseMedications/supplementsNumerous risk factorsNAFLD epidemiologyLiver transplantationCardiovascular mortalityLiver biopsySimple steatosisLiver diseaseMetabolic derangementsAssociated hepatitisDefinitive diagnosisPathologic changesFree fatty acidsAdvanced imagingLiver accumulationNatural historyProgressive steatosisGold standard